Aridis Pharmaceuticals Inc (ARDS) Receives $30.60 Average Target Price from Brokerages

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has received an average rating of “Buy” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $30.60.

Several research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Aridis Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Wednesday, May 29th. Maxim Group set a $25.00 price objective on shares of Aridis Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 16th. Finally, Northland Securities reissued a “buy” rating and set a $40.00 price objective on shares of Aridis Pharmaceuticals in a report on Wednesday, April 17th.

Aridis Pharmaceuticals stock opened at $9.68 on Friday. Aridis Pharmaceuticals has a 12-month low of $7.59 and a 12-month high of $13.85. The firm has a market cap of $70.53 million and a P/E ratio of -1.38.

Aridis Pharmaceuticals (NASDAQ:ARDS) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.87) by ($0.12). The firm had revenue of $1.02 million for the quarter. Aridis Pharmaceuticals had a negative return on equity of 1,961.31% and a negative net margin of 660.78%. As a group, analysts expect that Aridis Pharmaceuticals will post -3.11 earnings per share for the current fiscal year.

Aridis Pharmaceuticals Company Profile

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Recommended Story: What is Liquidity?

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply